Budapest XII

• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting
  2023-507525-42-00 5 2025-12-23 Endometrial cancer
• An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec … Recruiting
  2025-520582-51-00 5 2025-10-17 Hormone receptor positive breast cancer
• A Phase 3 Single-arm Study of UGN-104 for the Treatment of LG-UTUC Recruiting
  2024-519343-15-00 5 2025-10-08 Low-grade Upper Tract Urothelial Cancer
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 Non-Small Cell Lung Cancer
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10 … Recruiting
  2024-512659-19-00 10 2025-03-31 Advanced Melanoma
• A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c … Recruiting
  2023-505606-42-00 5 2024-10-15 Head and Neck Squamous Cell Carcinoma (HNSCC)
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 4 2024-10-02 Locally advanced or metastatic urothelial cancer
• A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a … Recruiting
  2023-509606-30-00 5 2024-07-24 Ulcerative colitis
• Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting
  2022-501105-12-00 5 2024-07-15 Urothelial Carcinoma
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c … Recruiting
  2023-504308-27-00 5 2024-06-06 non-squamous non-small cell lung cancer
• Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting
  2023-503523-25-00 4 2024-02-29 Non-small cell lung cancer
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po … Recruiting
  2023-505604-32-00 5 2024-01-24 Non small cell lung cancer (NSCLC)
• VB10.16 Plus Pembrolizumab in First Line r/m HNSCC Recruiting
  2022-503055-26-00 9 2023-10-30 Unresectable recurrent or metastatic HPV16 (Human Papilloma Virus) pos
• A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca … Recruiting
  2022-501703-27-00 5 2023-07-05 Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
• A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm … Recruiting
  2023-504595-26-00 4 2023-05-22 Non-Small Cell Lung Cancer
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)

Showing 25–48 of 311 trials